UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Drugs Made In America Acquisition Corp.
(Exact name of registrant as specified in its charter)
| Cayman Islands | | 99-2394788 |
(State or other jurisdiction of
incorporation or organization) | | (I.R.S. Employer
Identification No.) |
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301
(Address of principal executive offices, including zip code)
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class
to be registered | | Name of each exchange on which
each class is to be registered |
| | | |
| Ordinary Shares, par value of $0.0001 per share | | The Nasdaq Stock Market LLC |
| | | |
| Rights, each entitling the holder to receive one-eighth (1/8) of one Ordinary Share | | The Nasdaq Stock Market LLC |
| | | |
| Units, each consisting of one Ordinary Share and one Right to receive one-eighth (1/8) of one Ordinary Share | | The Nasdaq Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement file number to which this form relates: 333-281170.
Securities to be registered pursuant to Section 12(g) of the Act: None.
Item 1. Description of Registrant’s Securities to be Registered.
A description of the ordinary shares, rights and units to be registered hereunder is contained in the section entitled “Description of Securities” in the Prospectus included in Drugs Made In America Acquisition Corp.’s (the “Registrant”) Registration Statement on Form S-1 (File No. 333-281170) initially filed with the Securities and Exchange Commission on August 1, 2024, as amended from time to time (the “Registration Statement”). This information is incorporated herein by reference. Any form of prospectus or prospectus supplement to the Registration Statement that includes such descriptions and that is filed subsequently to the Registration Statement is hereby also incorporated by reference herein.
Item 2. Exhibits.
Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section l2 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
| Date: January 7, 2025 | DRUGS MADE IN AMERICA ACQUISITION CORP. |
| | | |
| | By: | /s/ Lynn Stockwell |
| | Name: | Lynn Stockwell |
| | Title: | Chief Executive Officer |
